USRE29835E
(en)
|
1971-06-01 |
1978-11-14 |
Icn Pharmaceuticals |
1,2,4-Triazole nucleosides
|
US3798209A
(en)
|
1971-06-01 |
1974-03-19 |
Icn Pharmaceuticals |
1,2,4-triazole nucleosides
|
US3994974A
(en)
|
1972-02-05 |
1976-11-30 |
Yamanouchi Pharmaceutical Co., Ltd. |
α-Aminomethylbenzyl alcohol derivatives
|
US3852267A
(en)
|
1972-08-04 |
1974-12-03 |
Icn Pharmaceuticals |
Phosphoramidates of 3{40 ,5{40 -cyclic purine nucleotides
|
US4138547A
(en)
|
1977-12-22 |
1979-02-06 |
Icn Pharmaceuticals, Inc. |
Process for preparing 1,2,4-triazole nucleosides
|
JPS57146593A
(en)
|
1981-03-09 |
1982-09-10 |
Ajinomoto Co Inc |
Preparation of ribofuranosyltriazole derivative
|
US4816570A
(en)
|
1982-11-30 |
1989-03-28 |
The Board Of Regents Of The University Of Texas System |
Biologically reversible phosphate and phosphonate protective groups
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
US5077056A
(en)
|
1984-08-08 |
1991-12-31 |
The Liposome Company, Inc. |
Encapsulation of antineoplastic agents in liposomes
|
US5736155A
(en)
|
1984-08-08 |
1998-04-07 |
The Liposome Company, Inc. |
Encapsulation of antineoplastic agents in liposomes
|
NL8403224A
(nl)
|
1984-10-24 |
1986-05-16 |
Oce Andeno Bv |
Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
|
US5223263A
(en)
|
1988-07-07 |
1993-06-29 |
Vical, Inc. |
Liponucleotide-containing liposomes
|
US5246937A
(en)
|
1985-09-18 |
1993-09-21 |
Beecham Group P.L.C. |
Purine derivatives
|
US4797285A
(en)
|
1985-12-06 |
1989-01-10 |
Yissum Research And Development Company Of The Hebrew University Of Jerusalem |
Lipsome/anthraquinone drug composition and method
|
US5154930A
(en)
|
1987-03-05 |
1992-10-13 |
The Liposome Company, Inc. |
Pharmacological agent-lipid solution preparation
|
GB8719367D0
(en)
|
1987-08-15 |
1987-09-23 |
Wellcome Found |
Therapeutic compounds
|
WO1989002733A1
(en)
|
1987-09-22 |
1989-04-06 |
The Regents Of The University Of California |
Liposomal nucleoside analogues for treating aids
|
IL91664A
(en)
|
1988-09-28 |
1993-05-13 |
Yissum Res Dev Co |
Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
|
US6132763A
(en)
|
1988-10-20 |
2000-10-17 |
Polymasc Pharmaceuticals Plc |
Liposomes
|
US5705363A
(en)
|
1989-03-02 |
1998-01-06 |
The Women's Research Institute |
Recombinant production of human interferon τ polypeptides and nucleic acids
|
US5549910A
(en)
|
1989-03-31 |
1996-08-27 |
The Regents Of The University Of California |
Preparation of liposome and lipid complex compositions
|
US5277914A
(en)
|
1989-03-31 |
1994-01-11 |
The Regents Of The University Of California |
Preparation of liposome and lipid complex compositions
|
US5077057A
(en)
|
1989-04-05 |
1991-12-31 |
The Regents Of The University Of California |
Preparation of liposome and lipid complex compositions
|
US5194654A
(en)
|
1989-11-22 |
1993-03-16 |
Vical, Inc. |
Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
|
US5411947A
(en)
|
1989-06-28 |
1995-05-02 |
Vestar, Inc. |
Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5225212A
(en)
|
1989-10-20 |
1993-07-06 |
Liposome Technology, Inc. |
Microreservoir liposome composition and method
|
US5463092A
(en)
|
1989-11-22 |
1995-10-31 |
Vestar, Inc. |
Lipid derivatives of phosphonacids for liposomal incorporation and method of use
|
US5026687A
(en)
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
ES2152922T3
(es)
|
1990-04-06 |
2001-02-16 |
Genelabs Tech Inc |
Epitopos del virus de la hepatitis c.
|
US5091188A
(en)
|
1990-04-26 |
1992-02-25 |
Haynes Duncan H |
Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
|
WO1991016920A1
(en)
|
1990-05-07 |
1991-11-14 |
Vical, Inc. |
Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
|
WO1991018914A1
(en)
|
1990-05-29 |
1991-12-12 |
Vical, Inc. |
Synthesis of glycerol di- and triphosphate derivatives
|
ES2083580T3
(es)
|
1990-06-13 |
1996-04-16 |
Arnold Glazier |
Profarmacos de fosforo.
|
US6060080A
(en)
|
1990-07-16 |
2000-05-09 |
Daiichi Pharmaceutical Co., Ltd. |
Liposomal products
|
JP2599492B2
(ja)
|
1990-08-21 |
1997-04-09 |
第一製薬株式会社 |
リポソーム製剤の製造法
|
DK0481214T3
(da)
|
1990-09-14 |
1999-02-22 |
Acad Of Science Czech Republic |
Prolægemidler af phosphonater
|
US5372808A
(en)
|
1990-10-17 |
1994-12-13 |
Amgen Inc. |
Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
|
US5149794A
(en)
|
1990-11-01 |
1992-09-22 |
State Of Oregon |
Covalent lipid-drug conjugates for drug targeting
|
US5543389A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization |
Covalent polar lipid-peptide conjugates for use in salves
|
US5256641A
(en)
|
1990-11-01 |
1993-10-26 |
State Of Oregon |
Covalent polar lipid-peptide conjugates for immunological targeting
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
US5595732A
(en)
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
US5157027A
(en)
|
1991-05-13 |
1992-10-20 |
E. R. Squibb & Sons, Inc. |
Bisphosphonate squalene synthetase inhibitors and method
|
EP0594677A4
(en)
|
1991-07-12 |
1997-09-17 |
Vical Inc |
Antiviral liponucleosides: treatment of hepatitis b
|
NZ243567A
(en)
|
1991-07-22 |
1995-04-27 |
Bristol Myers Squibb Co |
Pharmaceutical oral formulation of a dideoxy purine nucleoside comprising the nucleoside together with a water-insoluble antacid buffering composition
|
US5554728A
(en)
|
1991-07-23 |
1996-09-10 |
Nexstar Pharmaceuticals, Inc. |
Lipid conjugates of therapeutic peptides and protease inhibitors
|
TW224053B
(es)
|
1991-09-13 |
1994-05-21 |
Paul B Chretien |
|
DE4200821A1
(de)
|
1992-01-15 |
1993-07-22 |
Bayer Ag |
Geschmacksmaskierte pharmazeutische mittel
|
US5676942A
(en)
|
1992-02-10 |
1997-10-14 |
Interferon Sciences, Inc. |
Composition containing human alpha interferon species proteins and method for use thereof
|
US5405598A
(en)
|
1992-02-24 |
1995-04-11 |
Schinazi; Raymond F. |
Sensitizing agents for use in boron neutron capture therapy
|
US5610054A
(en)
|
1992-05-14 |
1997-03-11 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecule targeted against Hepatitis C virus
|
US5849905A
(en)
|
1994-11-23 |
1998-12-15 |
Centre National De La Recherche Scientifique |
Biologically active phosphotriester-type nucleosides and methods for preparing same
|
US5770725A
(en)
|
1992-05-25 |
1998-06-23 |
Gosselin; Gilles |
Phosphotriester type biologically active compounds
|
US6020482A
(en)
|
1992-05-25 |
2000-02-01 |
Gosselin; Gilles |
Phosphotriester type biologically active compounds
|
US5256798A
(en)
|
1992-06-22 |
1993-10-26 |
Eli Lilly And Company |
Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates
|
US5426183A
(en)
|
1992-06-22 |
1995-06-20 |
Eli Lilly And Company |
Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
|
IL106075A
(en)
|
1992-06-22 |
2000-12-06 |
Lilly Co Eli |
Process for preparing alpha-anomer enriched 1-halo-2-deoxy-2,2-difluoro-alpha-D-erythropentofuranose derivatives
|
IL106840A
(en)
|
1992-09-01 |
1998-09-24 |
Lilly Co Eli |
Process for basic anatomization of pentopornosyl nucleosides
|
GB9226729D0
(en)
|
1992-12-22 |
1993-02-17 |
Wellcome Found |
Therapeutic combination
|
US6096331A
(en)
|
1993-02-22 |
2000-08-01 |
Vivorx Pharmaceuticals, Inc. |
Methods and compositions useful for administration of chemotherapeutic agents
|
US6753006B1
(en)
|
1993-02-22 |
2004-06-22 |
American Bioscience, Inc. |
Paclitaxel-containing formulations
|
US6749868B1
(en)
|
1993-02-22 |
2004-06-15 |
American Bioscience, Inc. |
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
|
US5439686A
(en)
|
1993-02-22 |
1995-08-08 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
|
DK0693924T4
(da)
|
1993-02-22 |
2008-08-04 |
Abraxis Bioscience Inc |
Fremgangsmåde til (in vivo) levering af biologiske materialer og sammensætninger, der er egnede dertil
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
WO1994019012A2
(en)
|
1993-02-24 |
1994-09-01 |
Wang Jui H |
Compositions and methods of application of reactive antiviral polymers
|
US6180134B1
(en)
|
1993-03-23 |
2001-01-30 |
Sequus Pharmaceuticals, Inc. |
Enhanced ciruclation effector composition and method
|
EP0746319A4
(en)
|
1993-05-12 |
1997-11-05 |
Karl Y Hostetler |
ACYCLOVIR DERIVATIVES FOR TOPICAL USE
|
CA2167537A1
(en)
|
1993-07-19 |
1995-02-02 |
Tsuneo Ozeki |
Hepatitis c virus proliferation inhibitor
|
US7375198B2
(en)
|
1993-10-26 |
2008-05-20 |
Affymetrix, Inc. |
Modified nucleic acid probes
|
US6156501A
(en)
|
1993-10-26 |
2000-12-05 |
Affymetrix, Inc. |
Arrays of modified nucleic acid probes and methods of use
|
US5951974A
(en)
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
EP0730470B1
(en)
|
1993-11-10 |
2002-03-27 |
Enzon, Inc. |
Improved interferon polymer conjugates
|
AU6550394A
(en)
|
1994-03-11 |
1995-09-25 |
Isis Pharmaceuticals, Inc. |
Novel pyrimidine nucleosides
|
DE4447588C2
(de)
|
1994-05-03 |
1997-11-20 |
Omer Osama Dr Dr Med |
Pflanzliches Arzneimittel zur Behandlung von chronischen und allergischen Rhino-Sino-Bronchitiden
|
WO1995035102A1
(en)
|
1994-06-22 |
1995-12-28 |
Nexstar Pharmaceuticals, Inc. |
Novel method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement
|
US5840891A
(en)
|
1994-07-28 |
1998-11-24 |
Syntex (U.S.A.) Inc. |
2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
|
DE4432623A1
(de)
|
1994-09-14 |
1996-03-21 |
Huels Chemische Werke Ag |
Verfahren zur Bleichung von wäßrigen Tensidlösungen
|
US5738846A
(en)
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
US5696277A
(en)
|
1994-11-15 |
1997-12-09 |
Karl Y. Hostetler |
Antiviral prodrugs
|
US5703058A
(en)
|
1995-01-27 |
1997-12-30 |
Emory University |
Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
|
US6391859B1
(en)
|
1995-01-27 |
2002-05-21 |
Emory University |
[5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
|
GB9505025D0
(en)
|
1995-03-13 |
1995-05-03 |
Medical Res Council |
Chemical compounds
|
DE19514523A1
(de)
|
1995-04-12 |
1996-10-17 |
Schering Ag |
Neue Cytosin- und Cytidinderivate
|
DE69635864T2
(de)
|
1995-09-27 |
2006-10-26 |
Emory University |
Rekombinante rna-replikase von hepatitis-c-virus
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
US5767097A
(en)
|
1996-01-23 |
1998-06-16 |
Icn Pharmaceuticals, Inc. |
Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
|
GB9602028D0
(en)
|
1996-02-01 |
1996-04-03 |
Amersham Int Plc |
Nucleoside analogues
|
US5980884A
(en)
|
1996-02-05 |
1999-11-09 |
Amgen, Inc. |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
|
EP0914421A2
(en)
|
1996-02-29 |
1999-05-12 |
Immusol, Inc. |
Hepatitis c virus ribozymes
|
US5633388A
(en)
|
1996-03-29 |
1997-05-27 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5830905A
(en)
|
1996-03-29 |
1998-11-03 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5990276A
(en)
|
1996-05-10 |
1999-11-23 |
Schering Corporation |
Synthetic inhibitors of hepatitis C virus NS3 protease
|
GB9609932D0
(en)
|
1996-05-13 |
1996-07-17 |
Hoffmann La Roche |
Use of IL-12 and IFN alpha for the treatment of infectious diseases
|
US5891874A
(en)
|
1996-06-05 |
1999-04-06 |
Eli Lilly And Company |
Anti-viral compound
|
US5837257A
(en)
|
1996-07-09 |
1998-11-17 |
Sage R&D |
Use of plant extracts for treatment of HIV, HCV and HBV infections
|
US6214375B1
(en)
|
1996-07-16 |
2001-04-10 |
Generex Pharmaceuticals, Inc. |
Phospholipid formulations
|
US5922695A
(en)
|
1996-07-26 |
1999-07-13 |
Gilead Sciences, Inc. |
Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
|
US5922757A
(en)
|
1996-09-30 |
1999-07-13 |
The Regents Of The University Of California |
Treatment and prevention of hepatic disorders
|
TW520297B
(en)
|
1996-10-11 |
2003-02-11 |
Sequus Pharm Inc |
Fusogenic liposome composition and method
|
US6224903B1
(en)
|
1996-10-11 |
2001-05-01 |
Sequus Pharmaceuticals, Inc. |
Polymer-lipid conjugate for fusion of target membranes
|
US6509320B1
(en)
|
1996-10-16 |
2003-01-21 |
Icn Pharmaceuticals, Inc. |
Purine L-nucleosides, analogs and uses thereof
|
CZ120699A3
(cs)
|
1996-10-16 |
1999-09-15 |
Icn Pharmaceuticals, Inc. |
Monocyklická L-nukleosidová analoga a jejich využití
|
JP2001524936A
(ja)
|
1996-10-16 |
2001-12-04 |
アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド |
プリンl―ヌクレオシド類およびその用途
|
US6455690B1
(en)
|
1996-10-16 |
2002-09-24 |
Robert Tam |
L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
|
CA2268391A1
(en)
|
1996-10-18 |
1998-04-30 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
|
GB9623908D0
(en)
|
1996-11-18 |
1997-01-08 |
Hoffmann La Roche |
Amino acid derivatives
|
IL119833A
(en)
|
1996-12-15 |
2001-01-11 |
Lavie David |
Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
|
US5827533A
(en)
|
1997-02-06 |
1998-10-27 |
Duke University |
Liposomes containing active agents aggregated with lipid surfactants
|
US6004933A
(en)
|
1997-04-25 |
1999-12-21 |
Cortech Inc. |
Cysteine protease inhibitors
|
EA002254B1
(ru)
|
1997-06-30 |
2002-02-28 |
Мерц + Ко. Гмбх Унд Ко. |
1-аминоалкилциклогексановые антагонисты рецепторов nmda
|
ES2234144T3
(es)
|
1997-08-11 |
2005-06-16 |
Boehringer Ingelheim (Canada) Ltd. |
Analogos de peptidos inhibidores de la hepatitis c.
|
PT903148E
(pt)
|
1997-09-21 |
2002-02-28 |
Schering Corp |
Terapia de combinacao para a erradicacao de rna de hcv detectavel em doentes tendo infeccao cronica pelo virus da hepatite c
|
US6703374B1
(en)
|
1997-10-30 |
2004-03-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Nucleosides for imaging and treatment applications
|
US5981709A
(en)
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
CA2317505C
(en)
|
1998-01-23 |
2011-01-04 |
Newbiotics, Inc. |
Enzyme catalyzed therapeutic agents
|
KR100954390B1
(ko)
|
1998-02-25 |
2010-04-26 |
에모리 유니버시티 |
2'-플루오로뉴클레오사이드
|
US6312662B1
(en)
|
1998-03-06 |
2001-11-06 |
Metabasis Therapeutics, Inc. |
Prodrugs phosphorus-containing compounds
|
US6787305B1
(en)
|
1998-03-13 |
2004-09-07 |
Invitrogen Corporation |
Compositions and methods for enhanced synthesis of nucleic acid molecules
|
WO1999049873A1
(en)
|
1998-03-27 |
1999-10-07 |
Regents Of The University Of Minnesota |
Nucleosides with antiviral and anticancer activity
|
GB9806815D0
(en)
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
SK288038B6
(en)
|
1998-05-15 |
2013-01-02 |
Merck Sharp & Dohme |
Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection
|
US20010014352A1
(en)
|
1998-05-27 |
2001-08-16 |
Udit Batra |
Compressed tablet formulation
|
ES2251196T3
(es)
|
1998-06-08 |
2006-04-16 |
F. Hoffmann-La Roche Ag |
Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica.
|
US6726925B1
(en)
|
1998-06-18 |
2004-04-27 |
Duke University |
Temperature-sensitive liposomal formulation
|
US6200598B1
(en)
|
1998-06-18 |
2001-03-13 |
Duke University |
Temperature-sensitive liposomal formulation
|
GB9816358D0
(en)
|
1998-07-27 |
1998-09-23 |
Angeletti P Ist Richerche Bio |
Enzyme inhibitors
|
ES2244204T3
(es)
|
1998-07-27 |
2005-12-01 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Derivados de dicetoacidos como inhibidores de polimerasas.
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
CA2340156C
(en)
|
1998-08-10 |
2007-10-23 |
Novirio Pharmaceuticals Limited |
.beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
|
NZ511093A
(en)
|
1998-10-16 |
2003-04-29 |
Mercian Corp |
Crystallization of doxorubicin hydrochloride
|
US6635278B1
(en)
|
1998-12-15 |
2003-10-21 |
Gilead Sciences, Inc. |
Pharmaceutical formulations
|
AU2157000A
(en)
|
1998-12-18 |
2000-07-12 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction hcv combination therapy
|
US6267985B1
(en)
|
1999-06-30 |
2001-07-31 |
Lipocine Inc. |
Clear oil-containing pharmaceutical compositions
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
US6395300B1
(en)
|
1999-05-27 |
2002-05-28 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
US7919119B2
(en)
|
1999-05-27 |
2011-04-05 |
Acusphere, Inc. |
Porous drug matrices and methods of manufacture thereof
|
CN1079473C
(zh)
|
1999-05-31 |
2002-02-20 |
李岭群 |
预制梁连接筋
|
AU5905400A
(en)
|
1999-07-14 |
2001-02-05 |
Board Of Regents, The University Of Texas System |
Methods and compositions for delivery and retention of active agents to lymph nodes
|
BR0012896A
(pt)
|
1999-07-30 |
2002-06-18 |
Abbott Gmbh & Co Kg |
2-pirazolin-5-onas
|
US6752981B1
(en)
|
1999-09-08 |
2004-06-22 |
Metabasis Therapeutics, Inc. |
Prodrugs for liver specific drug delivery
|
US6566365B1
(en)
|
1999-11-04 |
2003-05-20 |
Biochem Pharma Inc. |
Method for the treatment of Flaviviridea viral infection using nucleoside analogues
|
EP1232166A2
(en)
|
1999-11-12 |
2002-08-21 |
Pharmasset Limited |
Synthesis of 2'-deoxy-l-nucleosides
|
US20060034937A1
(en)
|
1999-11-23 |
2006-02-16 |
Mahesh Patel |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US6495677B1
(en)
|
2000-02-15 |
2002-12-17 |
Kanda S. Ramasamy |
Nucleoside compounds
|
WO2001060315A2
(en)
|
2000-02-18 |
2001-08-23 |
Shire Biochem Inc. |
Method for the treatment or prevention of flavivirus infections using nucleoside analogues
|
CN100457118C
(zh)
|
2000-04-13 |
2009-02-04 |
法玛塞特有限公司 |
用于治疗肝炎病毒感染的3′-或2′-羟甲基取代的核苷衍生物
|
EP1282632A1
(en)
|
2000-04-20 |
2003-02-12 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
CN100490818C
(zh)
|
2000-05-26 |
2009-05-27 |
诺瓦蒂斯有限公司 |
β-L-2′-脱氧核苷在制备用于治疗丁型肝炎病毒感染的药物中的用途
|
US6787526B1
(en)
|
2000-05-26 |
2004-09-07 |
Idenix Pharmaceuticals, Inc. |
Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
|
NZ547204A
(en)
|
2000-05-26 |
2008-01-31 |
Idenix Cayman Ltd |
Methods and compositions for treating flaviviruses and pestiviruses
|
FR2810322B1
(fr)
|
2000-06-14 |
2006-11-10 |
Pasteur Institut |
PRODUCTION COMBINATOIRE D'ANALOGUES DE NUCLEOTIDES ET NUCLEOTIDES (XiTP)
|
MY141594A
(en)
|
2000-06-15 |
2010-05-14 |
Novirio Pharmaceuticals Ltd |
3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
|
US6815542B2
(en)
|
2000-06-16 |
2004-11-09 |
Ribapharm, Inc. |
Nucleoside compounds and uses thereof
|
US6680068B2
(en)
|
2000-07-06 |
2004-01-20 |
The General Hospital Corporation |
Drug delivery formulations and targeting
|
UA72612C2
(en)
|
2000-07-06 |
2005-03-15 |
|
Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
|
CN1446201A
(zh)
|
2000-07-21 |
2003-10-01 |
先灵公司 |
用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
JP2004504407A
(ja)
|
2000-07-21 |
2004-02-12 |
コルバス・インターナショナル・インコーポレイテッド |
C型肝炎ウイルスのns3−セリンプロテアーゼ阻害剤としての新規ペプチド
|
KR100749160B1
(ko)
|
2000-07-21 |
2007-08-14 |
길리애드 사이언시즈, 인코포레이티드 |
포스포네이트 뉴클레오티드 유사체의 전구 약물의 제조방법
|
AR034127A1
(es)
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
AR039558A1
(es)
|
2000-08-21 |
2005-02-23 |
Inspire Pharmaceuticals Inc |
Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
|
US7018985B1
(en)
|
2000-08-21 |
2006-03-28 |
Inspire Pharmaceuticals, Inc. |
Composition and method for inhibiting platelet aggregation
|
US6897201B2
(en)
|
2000-08-21 |
2005-05-24 |
Inspire Pharmaceuticals, Inc. |
Compositions and methods for the treatment of glaucoma or ocular hypertension
|
US20030008841A1
(en)
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
WO2002032414A2
(en)
|
2000-10-18 |
2002-04-25 |
Schering Corporation |
Ribavirin-pegylated interferon alfa hcv combination therapy
|
CN1646141B
(zh)
|
2000-10-18 |
2014-06-25 |
吉利德制药有限责任公司 |
用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
|
US6555677B2
(en)
|
2000-10-31 |
2003-04-29 |
Merck & Co., Inc. |
Phase transfer catalyzed glycosidation of an indolocarbazole
|
AU2002248147B2
(en)
|
2000-11-20 |
2006-04-06 |
Bristol-Myers Squibb Company |
Hepatitis C tripeptide inhibitors
|
KR20030091946A
(ko)
|
2000-12-12 |
2003-12-03 |
쉐링 코포레이션 |
C형 간염 바이러스의 ns3-세린 프로테아제억제제로서의 디아릴 펩티드
|
US6727366B2
(en)
|
2000-12-13 |
2004-04-27 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
|
AU2002230763A1
(en)
|
2000-12-13 |
2008-01-03 |
Bristol-Myers Squibb Pharma Company |
Inhibitors of hepatitis c virus ns3 protease
|
KR20030081343A
(ko)
|
2000-12-15 |
2003-10-17 |
파마셋, 리미티드 |
플라비비리다에 감염 치료용 항바이러스제
|
EP1355916B1
(en)
|
2001-01-22 |
2007-01-10 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
US7105499B2
(en)
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
MY129350A
(en)
|
2001-04-25 |
2007-03-30 |
Bristol Myers Squibb Co |
Aripiprazole oral solution
|
GB0112617D0
(en)
|
2001-05-23 |
2001-07-18 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
GB0114286D0
(en)
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
US20050009775A1
(en)
|
2001-06-21 |
2005-01-13 |
Howes Peter David |
Nucleoside compounds in hcv
|
NZ530000A
(en)
|
2001-07-11 |
2007-03-30 |
Vertex Pharma |
Peptidomimetic bridged bicyclic serine protease inhibitors
|
EP2335700A1
(en)
|
2001-07-25 |
2011-06-22 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C virus polymerase inhibitors with a heterobicylic structure
|
ES2208540T3
(es)
|
2001-07-30 |
2004-06-16 |
Clariant Life Science Molecules (Italia) Spa |
Procedimiento para la preparacion de ribavirina.
|
EP1412369B1
(en)
|
2001-08-02 |
2008-05-07 |
Ilex Oncology, Inc. |
Process for preparing purine nucleosides
|
US6962991B2
(en)
|
2001-09-12 |
2005-11-08 |
Epoch Biosciences, Inc. |
Process for the synthesis of pyrazolopyrimidines
|
EP1432721A4
(en)
|
2001-09-13 |
2008-02-20 |
Bristol Myers Squibb Co |
PROCESS FOR THE PREPARATION OF REBECCAMYCIN AND ANALOGUE THEREOF
|
WO2003024461A1
(en)
|
2001-09-20 |
2003-03-27 |
Schering Corporation |
Hcv combination therapy
|
EP1435974A4
(en)
|
2001-09-28 |
2006-09-06 |
Idenix Cayman Ltd |
METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS WITH 4'-MODIFIED NUCLEOSIDES
|
DE60221875T2
(de)
|
2001-11-02 |
2007-12-20 |
Glaxo Group Ltd., Greenford |
4-(6-gliedrige)-heteroaryl-acyl-pyrrolidinderivate als hcv-inhibitoren
|
EP1448170A4
(en)
|
2001-11-27 |
2010-05-12 |
Bristol Myers Squibb Co |
EFAVIRENZ STAMP PREPARATIONS HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS
|
GB0129945D0
(en)
|
2001-12-13 |
2002-02-06 |
Mrc Technology Ltd |
Chemical compounds
|
KR100978904B1
(ko)
|
2001-12-14 |
2010-08-31 |
파마셋 인코포레이티드 |
바이러스 감염 치료용 n4-아실사이토신 뉴클레오사이드
|
AU2002353165A1
(en)
|
2001-12-17 |
2003-06-30 |
Ribapharm Inc. |
Deazapurine nucleoside libraries and compounds
|
CA2470521A1
(en)
|
2001-12-21 |
2003-07-10 |
Micrologix Biotech Inc. |
Anti-viral 7-deaza l-nucleosides
|
WO2003062256A1
(en)
|
2002-01-17 |
2003-07-31 |
Ribapharm Inc. |
2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
|
US7070801B2
(en)
|
2002-01-30 |
2006-07-04 |
National Institute Of Advanced Industrial Science And Technology |
Sugar-modified liposome and products comprising the liposome
|
CA2370396A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
WO2003068244A1
(en)
|
2002-02-13 |
2003-08-21 |
Merck & Co., Inc. |
Methods of inhibiting orthopoxvirus replication with nucleoside compounds
|
US20040023901A1
(en)
|
2002-02-28 |
2004-02-05 |
Cook Phillip D. |
Nucleoside 5'-monophosphate mimics and their prodrugs
|
EP1485395A4
(en)
|
2002-02-28 |
2011-04-13 |
Biota Scient Management |
NUCLEOTIDE MIMETICS AND PRODRUGS THEREOF
|
CN1313472C
(zh)
|
2002-04-26 |
2007-05-02 |
吉里德科学公司 |
Hiv蛋白酶抑制剂化合物的膦酸酯类似物的细胞蓄积及这类化合物
|
US20040014108A1
(en)
|
2002-05-24 |
2004-01-22 |
Eldrup Anne B. |
Oligonucleotides having modified nucleoside units
|
WO2003106477A1
(en)
|
2002-06-01 |
2003-12-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
|
MXPA04012245A
(es)
|
2002-06-04 |
2005-09-30 |
Neogenesis Pharmaceuticals Inc |
Compuestos de pirazolo[1,5a]pirimidina como agentes antivirales.
|
US7449488B2
(en)
|
2002-06-04 |
2008-11-11 |
Schering Corporation |
Pyrazolopyrimidines as protein kinase inhibitors
|
WO2003104250A1
(en)
|
2002-06-07 |
2003-12-18 |
Kylix, B. V. |
New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
|
AU2003251524A1
(en)
|
2002-06-17 |
2003-12-31 |
Isis Pharmaceuticals, Inc. |
Carbocyclic nucleoside analogs as RNA-antivirals
|
WO2004000858A2
(en)
|
2002-06-21 |
2003-12-31 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
US20060234962A1
(en)
|
2002-06-27 |
2006-10-19 |
Olsen David B |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
MXPA04012709A
(es)
|
2002-06-28 |
2005-09-30 |
Idenix Cayman Ltd |
Profarmacos modificados de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
|
KR20050055630A
(ko)
|
2002-06-28 |
2005-06-13 |
이데닉스 (케이만) 리미티드 |
플라비비리다에 감염 치료를 위한 1'-, 2'- 및 3'-변형된뉴클레오시드 유도체
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
JP2005533824A
(ja)
|
2002-06-28 |
2005-11-10 |
イデニクス(ケイマン)リミテツド |
フラビウイルス科感染の治療のための2’−c−メチル−3’−o−l−バリンエステルリボフラノシルシチジン
|
MXPA05000256A
(es)
|
2002-07-01 |
2005-07-15 |
Upjohn Co |
Inhibidores de polimerasa ns5b del vhc.
|
US6973905B2
(en)
|
2002-07-01 |
2005-12-13 |
Cinetic Automation Corporation |
Valve lash adjustment apparatus and method
|
BR0305426A
(pt)
|
2002-07-01 |
2004-08-24 |
Upjohn Co |
Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
|
EP1556399A4
(en)
|
2002-07-16 |
2007-09-26 |
Merck & Co Inc |
NUCLEOSIDE DERIVATIVES AS RNA-DEPENDENT VIRAL RNA POLYMERASE INHIBITORS
|
EP1572709A3
(en)
|
2002-07-24 |
2005-11-23 |
PTC Therapeutics, Inc. |
Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
|
AU2003256619A1
(en)
|
2002-07-24 |
2004-02-09 |
Isis Pharmaceuticals, Inc. |
Pyrrolopyrimidine thionucleoside analogs as antivirals
|
US20050026853A1
(en)
|
2002-07-25 |
2005-02-03 |
Micrologix Biotech Inc. |
Anti-viral 7-deaza D-nucleosides and uses thereof
|
US20050069522A1
(en)
|
2002-08-12 |
2005-03-31 |
Richard Colonno |
Combination pharmaceutical agents as inhibitors of HCV replication
|
SI1572095T1
(sl)
|
2002-09-13 |
2015-12-31 |
Novartis Ag |
Beta-l-2'-deoksinukleozidi za uporabo pri zdravljenju odpornih sevov hbv
|
JP2006505571A
(ja)
|
2002-10-15 |
2006-02-16 |
リゲル ファーマシューテイカルズ、インコーポレイテッド |
置換されたインドール及びhcv阻害剤としてのその使用
|
US20040229840A1
(en)
|
2002-10-29 |
2004-11-18 |
Balkrishen Bhat |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
HN2003000348A
(es)
|
2002-11-01 |
2008-10-14 |
Viropharma Inc |
Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
|
AU2003291755A1
(en)
|
2002-11-05 |
2004-06-07 |
Isis Pharmaceuticals, Inc. |
Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
|
AU2003291753B2
(en)
|
2002-11-05 |
2010-07-08 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
WO2004046331A2
(en)
|
2002-11-15 |
2004-06-03 |
Idenix (Cayman) Limited |
2’-branched nucleosides and flaviviridae mutation
|
TWI332507B
(en)
|
2002-11-19 |
2010-11-01 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
JP2006524632A
(ja)
|
2002-12-09 |
2006-11-02 |
アメリカン バイオサイエンス、インコーポレイテッド |
組成物及び薬物送達方法
|
WO2004052899A2
(en)
|
2002-12-12 |
2004-06-24 |
Idenix (Cayman) Limited |
Process for the production of 2'-branched nucleosides
|
US20040224916A1
(en)
|
2003-01-14 |
2004-11-11 |
Gilead Sciences, Inc. |
Compositions and methods for combination antiviral therapy
|
US7223785B2
(en)
|
2003-01-22 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
AU2003225705A1
(en)
|
2003-03-07 |
2004-09-30 |
Ribapharm Inc. |
Cytidine analogs and methods of use
|
WO2004084453A2
(en)
|
2003-03-20 |
2004-09-30 |
Microbiologica Quimica E Farmaceutica Ltd. |
METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
|
ATE422895T1
(de)
|
2003-04-16 |
2009-03-15 |
Bristol Myers Squibb Co |
Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
|
US20050261237A1
(en)
|
2003-04-25 |
2005-11-24 |
Boojamra Constantine G |
Nucleoside phosphonate analogs
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
KR20060061930A
(ko)
|
2003-04-25 |
2006-06-08 |
길리애드 사이언시즈, 인코포레이티드 |
항암성 포스포네이트 유사체
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
EA014685B1
(ru)
|
2003-04-25 |
2010-12-30 |
Джилид Сайэнс, Инк. |
Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
AU2004233897A1
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Kinase inhibitor phosphonate conjugates
|
US20040259934A1
(en)
|
2003-05-01 |
2004-12-23 |
Olsen David B. |
Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
|
WO2004096210A1
(en)
|
2003-05-01 |
2004-11-11 |
Glaxo Group Limited |
Acylated indoline and tetrahydroquinoline derivatives as hcv inhibitors
|
US20040229839A1
(en)
|
2003-05-14 |
2004-11-18 |
Biocryst Pharmaceuticals, Inc. |
Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
|
WO2005020884A2
(en)
|
2003-05-14 |
2005-03-10 |
Idenix (Cayman) Limited |
Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
|
WO2004106356A1
(en)
|
2003-05-27 |
2004-12-09 |
Syddansk Universitet |
Functionalized nucleotide derivatives
|
WO2005003147A2
(en)
|
2003-05-30 |
2005-01-13 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
EP1644479A4
(en)
|
2003-06-16 |
2008-04-23 |
Mark W Grinstaff |
MACROMOLECULES AND FUNCTIONAL SYNTHETIC MOLECULES FOR GENES ADMINISTRATION
|
GB0317009D0
(en)
|
2003-07-21 |
2003-08-27 |
Univ Cardiff |
Chemical compounds
|
ATE478886T1
(de)
|
2003-07-25 |
2010-09-15 |
Idenix Pharmaceuticals Inc |
Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
|
DE602004029904D1
(de)
|
2003-08-27 |
2010-12-16 |
Biota Scient Management |
Neue tricyclische nukleoside oder nukleotide als therapeutische mittel
|
AU2004274021B2
(en)
|
2003-09-18 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
4'-thionucleosides and oligomeric compounds
|
US20050119189A1
(en)
|
2003-09-18 |
2005-06-02 |
Cottrell Kevin M. |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
US20050148534A1
(en)
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
US7491794B2
(en)
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
CA2540858C
(en)
|
2003-10-14 |
2009-12-08 |
Intermune, Inc. |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
|
RU2006118359A
(ru)
|
2003-10-27 |
2007-12-10 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Комбинации для лечения вирусного гепатита с (hcv)
|
US7026339B2
(en)
|
2003-11-07 |
2006-04-11 |
Fan Yang |
Inhibitors of HCV NS5B polymerase
|
TW200528459A
(en)
|
2004-01-06 |
2005-09-01 |
Achillion Pharmaceuticals Inc |
Azabenzofuran substituted thioureas; inhibitors of viral replication
|
US20070155731A1
(en)
|
2004-01-28 |
2007-07-05 |
Gabor Butora |
Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity
|
AU2005216971A1
(en)
|
2004-02-25 |
2005-09-09 |
Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Office Of Technology Transfer |
Methylation inhibitor compounds
|
WO2005087788A2
(en)
|
2004-03-04 |
2005-09-22 |
The Regents Of The University Of California |
Methods for preparation of nucleoside phosphonate esters
|
AU2005228894B9
(en)
|
2004-03-30 |
2011-10-13 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
GB0408995D0
(en)
|
2004-04-22 |
2004-05-26 |
Glaxo Group Ltd |
Compounds
|
JP2008501693A
(ja)
|
2004-06-03 |
2008-01-24 |
アイシス ファーマシューティカルズ、インク. |
遺伝子調節で使用するための個別に調節された鎖を有する二本鎖組成物
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7534767B2
(en)
|
2004-06-15 |
2009-05-19 |
Merck & Co., Inc. |
C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
|
WO2006000922A2
(en)
|
2004-06-23 |
2006-01-05 |
Idenix (Cayman) Limited |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
CA2571079A1
(en)
|
2004-06-24 |
2006-02-02 |
Merck & Co., Inc. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
US7217523B2
(en)
|
2004-07-02 |
2007-05-15 |
Regents Of The University Of Minnesota |
Nucleoside phosphoramidates and nucleoside phosphoramidases
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
KR101235548B1
(ko)
|
2004-07-21 |
2013-02-21 |
길리어드 파마셋 엘엘씨 |
2'-데옥시-2'-플루오로-2'-C-메틸-β-D-리보퓨라노실 뉴클레오사이드의 제조 방법
|
ATE505196T1
(de)
|
2004-07-27 |
2011-04-15 |
Gilead Sciences Inc |
Nukleosid phosphonat konjugate als anti hiv mittel
|
US7348425B2
(en)
|
2004-08-09 |
2008-03-25 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
US7153848B2
(en)
|
2004-08-09 |
2006-12-26 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
CA2577526A1
(en)
|
2004-08-23 |
2006-03-02 |
Joseph Armstrong Martin |
Antiviral 4'-azido-nucleosides
|
ATE437875T1
(de)
|
2004-08-23 |
2009-08-15 |
Hoffmann La Roche |
Heterozyklische antivirale verbindungen
|
WO2006029081A2
(en)
|
2004-09-02 |
2006-03-16 |
Neopharm, Inc. |
Nucleoside-lipid conjugates, their method of preparation and uses thereof
|
EP1809301B1
(en)
|
2004-09-14 |
2019-11-06 |
Gilead Pharmasset LLC |
2-fluoro-2-alkyl-substituted d-ribonolactone intermediates
|
JP2008514639A
(ja)
|
2004-09-24 |
2008-05-08 |
イデニクス(ケイマン)リミテツド |
フラビウイルス、ペスチウイルス及びヘパシウイルスの感染症を治療するための方法及び組成物
|
KR20070058602A
(ko)
|
2004-09-30 |
2007-06-08 |
티보텍 파마슈티칼즈 리미티드 |
Hcv 저해 바이-사이클릭 피리미딘
|
AU2005317081A1
(en)
|
2004-10-21 |
2006-06-22 |
Merck & Co., Inc. |
Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
|
JP2008523082A
(ja)
|
2004-12-09 |
2008-07-03 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
抗菌活性および抗癌活性を有するヌクレオチド
|
WO2006065590A2
(en)
|
2004-12-16 |
2006-06-22 |
Xtl Biopharmaceuticals Inc. |
Pyridine and pyrimidine antiviral compositions
|
EP1828217A2
(en)
|
2004-12-16 |
2007-09-05 |
Febit Biotech GmbH |
Polymerase-independent analysis of the sequence of polynucleotides
|
WO2006093801A1
(en)
|
2005-02-25 |
2006-09-08 |
Abbott Laboratories |
Thiadiazine derivatives useful as anti-infective agents
|
US7524825B2
(en)
|
2005-02-28 |
2009-04-28 |
Smithkline Beecham Corporation |
Tricyclic-nucleoside compounds for treating viral infections
|
US8802840B2
(en)
|
2005-03-08 |
2014-08-12 |
Biota Scientific Management Pty Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
JP2008534479A
(ja)
|
2005-03-25 |
2008-08-28 |
テイボテク・フアーマシユーチカルズ・リミテツド |
Hcvの複素二環式阻害剤
|
AR056327A1
(es)
|
2005-04-25 |
2007-10-03 |
Genelabs Tech Inc |
Compuestos de nucleosidos para el tratamiento de infecciones virales
|
WO2006119347A1
(en)
|
2005-05-02 |
2006-11-09 |
Pharmaessentia Corp. |
STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
|
WO2006121820A1
(en)
|
2005-05-05 |
2006-11-16 |
Valeant Research & Development |
Phosphoramidate prodrugs for treatment of viral infection
|
AR054122A1
(es)
|
2005-05-12 |
2007-06-06 |
Tibotec Pharm Ltd |
Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas
|
AR056347A1
(es)
|
2005-05-12 |
2007-10-03 |
Tibotec Pharm Ltd |
Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
|
WO2007027248A2
(en)
|
2005-05-16 |
2007-03-08 |
Valeant Research & Development |
3', 5' - cyclic nucleoside analogues for treatment of hcv
|
WO2006130627A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods for treating hepatitis c
|
US8143288B2
(en)
|
2005-06-06 |
2012-03-27 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
TWI471145B
(zh)
|
2005-06-13 |
2015-02-01 |
Bristol Myers Squibb & Gilead Sciences Llc |
單一式藥學劑量型
|
TWI375560B
(en)
|
2005-06-13 |
2012-11-01 |
Gilead Sciences Inc |
Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
|
US20060293752A1
(en)
|
2005-06-27 |
2006-12-28 |
Missoum Moumene |
Intervertebral disc prosthesis and associated methods
|
EP2305697A3
(en)
|
2005-07-25 |
2011-07-27 |
Intermune, Inc. |
Macrocyclic inhibitors of Hepatitis C virus replication
|
EP1912730A2
(en)
|
2005-07-28 |
2008-04-23 |
Isp Investments Inc. |
Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
|
RU2441870C2
(ru)
|
2005-07-29 |
2012-02-10 |
Тиботек Фармасьютикалз Лтд. |
Макроциклические ингибиторы вируса гепатита с
|
PL1919898T3
(pl)
|
2005-07-29 |
2011-06-30 |
Tibotec Pharm Ltd |
Makrocykliczne inhibitory wirusa zapalenia wątroby typu C
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
US8012939B2
(en)
|
2005-07-29 |
2011-09-06 |
Tibotec Pharmaceuticals Ltd. Co |
Macrocyclic inhibitors of hepatitis C virus
|
BRPI0614637A2
(pt)
|
2005-07-29 |
2011-04-12 |
Tibotec Pharm Ltd |
inibidores macrocìclicos do vìrus da hepatite c
|
WO2007013047A2
(en)
|
2005-07-29 |
2007-02-01 |
Ranbaxy Laboratories Limited |
Water-dispersible anti-retroviral pharmaceutical compositions
|
JP2009507210A
(ja)
|
2005-07-29 |
2009-02-19 |
オートモーティブ システムズ ラボラトリー インコーポレーテッド |
磁気衝突センサー
|
EP1928475B1
(en)
|
2005-08-15 |
2018-05-23 |
Riboscience LLC |
Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides
|
GB0519478D0
(en)
|
2005-09-23 |
2005-11-02 |
Glaxo Group Ltd |
Compounds
|
GB0519488D0
(en)
|
2005-09-23 |
2005-11-02 |
Glaxo Group Ltd |
Compounds
|
CA2632626C
(en)
|
2005-12-09 |
2011-10-11 |
F. Hoffmann-La Roche Ag |
Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection
|
RU2008128452A
(ru)
|
2005-12-12 |
2010-01-20 |
Дженелабс Текнолоджис, Инк. (Us) |
Соединения n-(6-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
|
JP2009521479A
(ja)
|
2005-12-21 |
2009-06-04 |
アボット・ラボラトリーズ |
抗ウイルス化合物
|
US7763731B2
(en)
|
2005-12-21 |
2010-07-27 |
Abbott Laboratories |
Anti-viral compounds
|
GB0602046D0
(en)
|
2006-02-01 |
2006-03-15 |
Smithkline Beecham Corp |
Compounds
|
WO2007092000A1
(en)
|
2006-02-06 |
2007-08-16 |
Bristol-Myers Squibb Company |
Inhibitors of hcv replication
|
JP2009526850A
(ja)
|
2006-02-14 |
2009-07-23 |
メルク エンド カムパニー インコーポレーテッド |
Rna依存性rnaウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート
|
WO2007093901A1
(en)
|
2006-02-17 |
2007-08-23 |
Pfizer Limited |
3 -deazapurine derivatives as tlr7 modulators
|
US8895531B2
(en)
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
WO2007140200A2
(en)
|
2006-05-25 |
2007-12-06 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
|
DE602007006796D1
(de)
|
2006-05-25 |
2010-07-08 |
Bristol Myers Squibb Co |
Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
|
KR20140004808A
(ko)
|
2006-07-07 |
2014-01-13 |
길리애드 사이언시즈, 인코포레이티드 |
치료제의 약동학 특성의 모듈레이터
|
EP2043613A1
(en)
|
2006-07-14 |
2009-04-08 |
Fmc Corporation |
Solid form
|
EP1881001A1
(en)
|
2006-07-20 |
2008-01-23 |
Tibotec Pharmaceuticals Ltd. |
HCV NS-3 serine protease inhibitors
|
US8329159B2
(en)
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
RU2421461C2
(ru)
|
2006-10-10 |
2011-06-20 |
Фармассет, Инк. |
Способ получения рибофуранозил-пиримидиновых нуклеозидов
|
PL216525B1
(pl)
|
2006-10-17 |
2014-04-30 |
Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk |
5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
|
GB0623493D0
(en)
|
2006-11-24 |
2007-01-03 |
Univ Cardiff |
Chemical compounds
|
US8148349B2
(en)
|
2006-12-20 |
2012-04-03 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
|
US20080261913A1
(en)
|
2006-12-28 |
2008-10-23 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of liver disorders
|
JP2010515680A
(ja)
|
2007-01-05 |
2010-05-13 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Rna依存性rnaウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
GB0709791D0
(en)
|
2007-05-22 |
2007-06-27 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
CN101108870A
(zh)
|
2007-08-03 |
2008-01-23 |
冷一欣 |
核苷磷酸酯类化合物及制备方法和应用
|
US8629171B2
(en)
|
2007-08-08 |
2014-01-14 |
Bristol-Myers Squibb Company |
Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
|
NZ583825A
(en)
|
2007-09-14 |
2012-06-29 |
Schering Corp |
Method of treating hepatitis C patients comprising an HCV protease inhibitor, an antiviral compound and an interferon
|
JO2778B1
(en)
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain vehicles, installations and methods
|
JP5238939B2
(ja)
|
2007-11-07 |
2013-07-17 |
三菱化学株式会社 |
長繊維強化複合樹脂組成物および成形品
|
US20090318380A1
(en)
|
2007-11-20 |
2009-12-24 |
Pharmasset, Inc. |
2',4'-substituted nucleosides as antiviral agents
|
AR069740A1
(es)
|
2007-11-29 |
2010-02-17 |
Metabasis Therapeutics Inc |
Compuestos nucleosidos antivirales
|
US20090176732A1
(en)
|
2007-12-21 |
2009-07-09 |
Alios Biopharma Inc. |
Protected nucleotide analogs
|
US8227431B2
(en)
|
2008-03-17 |
2012-07-24 |
Hetero Drugs Limited |
Nucleoside derivatives
|
WO2009120878A2
(en)
|
2008-03-26 |
2009-10-01 |
Alnylam Pharmaceuticals, Inc. |
Non-natural ribonucleotides, and methods of use thereof
|
EA201071034A1
(ru)
|
2008-04-15 |
2011-06-30 |
Интермьюн, Инк. |
Новые макроциклические ингибиторы репликаций вируса гепатита с
|
WO2009129120A2
(en)
|
2008-04-15 |
2009-10-22 |
Rfs Pharma, Llc |
Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
|
AU2009240630B2
(en)
|
2008-04-23 |
2013-07-18 |
Gilead Sciences, Inc. |
Carba-nucleoside analogs for antiviral treatment
|
WO2010036407A2
(en)
|
2008-05-15 |
2010-04-01 |
Biocryst Pharmaceuticals, Inc. |
Antiviral nucleoside analogs
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
WO2010002877A2
(en)
|
2008-07-03 |
2010-01-07 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
WO2010042834A1
(en)
|
2008-10-09 |
2010-04-15 |
Anadys Pharmaceuticals, Inc. |
A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
|
US8716263B2
(en)
|
2008-12-23 |
2014-05-06 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
EP3222628A1
(en)
|
2008-12-23 |
2017-09-27 |
Gilead Pharmasset LLC |
Nucleoside phosphoramidates
|
US8551973B2
(en)
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
CA2748792A1
(en)
|
2009-01-07 |
2010-07-15 |
Samuel Earl Hopkins |
Combination of a cyclosporine derivative and nucleosides for treating hcv
|
ES2453078T3
(es)
|
2009-02-10 |
2014-04-03 |
Gilead Sciences, Inc. |
Análogos de carba-nucleósido para tratamiento antiviral
|
JO3027B1
(ar)
*
|
2009-05-14 |
2016-09-05 |
Janssen Products Lp |
نيوكليوسيدات يوراسيل سبيرواوكسيتان
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
PT3290428T
(pt)
|
2010-03-31 |
2021-12-27 |
Gilead Pharmasset Llc |
Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
|
AU2011336632B2
(en)
|
2010-11-30 |
2015-09-03 |
Gilead Pharmasset Llc |
Compounds
|